Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
PT Bundamedik Tbk's 3-Year RORE % for the quarter that ended in Mar. 2026 was 0.38%.
The industry rank for PT Bundamedik Tbk's 3-Year RORE % or its related term are showing as below:
ISX:BMHS's 3-Year RORE % is ranked worse than 50.25% of 601
companies
in the Healthcare Providers & Services industry
Industry Median: 0.74
vs ISX:BMHS: 0.38
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
PT Bundamedik Tbk 3-Year RORE % Related Terms
PT Bundamedik Tbk 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for PT Bundamedik Tbk's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:BMHS vs HCA, THC, DVA: 3-Year RORE % Comparison
For the Medical Care Facilities subindustry, PT Bundamedik Tbk's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Bundamedik Tbk 3-Year RORE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PT Bundamedik Tbk's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where PT Bundamedik Tbk's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
PT Bundamedik Tbk (ISX:BMHS) has a 3-Year RORE % of 0.38 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on PT Bundamedik Tbk and its competitors. According to the industry distribution chart, PT Bundamedik Tbk ranks #302 out of 601 companies in the Healthcare Providers & Services industry, placing it in the top 50.2%.
Is PT Bundamedik Tbk's 3-Year RORE % too high?
PT Bundamedik Tbk's current 3-Year RORE % is 0.38. The Healthcare Providers & Services industry median 3-Year RORE % is 0.74. PT Bundamedik Tbk's value of 0.38 is 48.6% below this industry median. Based on the distribution chart, PT Bundamedik Tbk ranks #302 out of 601 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, PT Bundamedik Tbk has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PT Bundamedik Tbk's 3-Year RORE % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, PT Bundamedik Tbk ranks #302 out of 601 companies for 3-Year RORE %. This places PT Bundamedik Tbk in the lower half of its industry. The industry median 3-Year RORE % is 0.74. PT Bundamedik Tbk's value of 0.38 is 48.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Healthcare Providers & Services company?
The median 3-Year RORE % among Healthcare Providers & Services companies is 0.74, based on 601 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Bundamedik Tbk's current 3-Year RORE % of 0.38 is 48.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on PT Bundamedik Tbk and its competitors. For the Healthcare Providers & Services industry, the median 3-Year RORE % is 0.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Bundamedik Tbk's current 3-Year RORE % is 0.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Bundamedik Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Bundamedik Tbk (ISX:BMHS) is currently considered Possible Value Trap. The stock's GF Value™ is Rp310.28, compared to a current price of Rp183.00 — trading 41% below its estimated fair value. The current 3-Year RORE % is 0.38 and 48.6% below the Healthcare Providers & Services industry median of 0.74. PT Bundamedik Tbk's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For PT Bundamedik Tbk (ISX:BMHS), the current 3-Year RORE % is 0.38 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Bundamedik Tbk (ISX:BMHS) Overvalued in 2026?
Based on GuruFocus' analysis, PT Bundamedik Tbk stock appears to be undervalued.
The current stock price of Rp183.00 is trading 41% below its estimated GF Value™ of Rp310.28.
GuruFocus considers PT Bundamedik Tbk to be Possible Value Trap.
Key valuation signals for ISX:BMHS:
3-Year RORE %: 0.38
GF Value™: Rp310.28 vs. price of Rp183.00 (41% below fair value)
Industry Position: 48.6% below the Healthcare Providers & Services median (#302 of 601)
No single metric tells the full story. See the ISX:BMHS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Bundamedik Tbk is a healthcare service provider. The Company carries out its main business activities through private hospital activities. It offers maternal and child health services, outpatient services, inpatient services, emergency services, service excellence centers, IVF services, and Clinical laboratory services.
65GF Score
Get the complete analysis for ISX:BMHS
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:BMHS has been successfully added to your 
